Research ArticleOriginal Article
Open Access

Temporal radiomics for non-invasive preoperative prediction of pathologic complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

Sunyi Zheng, Shuo Wang, Ziwei Feng, Jing Liang, Jiaxin Liu, Xiaomeng Yang, Zhanshuo Zhang, Yuechen Cui, Jiping Xie, Shuxuan Fan, Jing Wang, Guoqing Liao, Haiyu Zhou, Zhaoxiang Ye, Jianyu Xiao, Lei Shi, Xiaonan Cui and Dongsheng Yue
Cancer Biology & Medicine January 2026, 20250327; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0327

References

  1. 1.↵
    2. Siegel RL,
    3. Kratzer TB,
    4. Giaquinto AN,
    5. Sung H,
    6. Jemal A.
    Cancer statistics, 2025. CA Cancer J Clin. 2025; 75: 10–45.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Zheng S,
    3. Liu J,
    4. Xie J,
    5. Zhang W,
    6. Bian K,
    7. Liang J, et al.
    Differentiating high-grade patterns and predominant subtypes for IASLC grading in invasive pulmonary adenocarcinoma using radiomics and clinical-semantic features. Cancer Imaging. 2025; 25: 42.
    OpenUrlPubMed
  3. 3.↵
    2. Wozniak AJ,
    3. Gadgeel SM.
    Adjuvant therapy for resected non-small cell lung cancer. Ther Adv Med Oncol. 2009; 1: 109–18.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Felip E,
    3. Altorki N,
    4. Zhou C,
    5. Vallières E,
    6. Martínez-Martí A,
    7. Rittmeyer A, et al.
    Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023; 34: 907–19.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Yue D,
    3. Wang W,
    4. Liu H,
    5. Chen Q,
    6. Chen C,
    7. Zhang J, et al.
    LBA58 pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDB) chemotherapy (CT) in resectable stage II–IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial. Ann Oncol. 2023; 34: S1299.
    OpenUrl
  6. 6.
    2. Forde PM,
    3. Spicer J,
    4. Lu S,
    5. Provencio M,
    6. Mitsudomi T,
    7. Awad MM, et al.
    Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022; 386: 1973–85.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Heymach JV,
    3. Harpole D,
    4. Mitsudomi T,
    5. Taube JM,
    6. Galffy G,
    7. Hochmair M, et al.
    Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023; 389: 1672–84.
    OpenUrlCrossRefPubMed
  8. 8.
    2. Wakelee H,
    3. Liberman M,
    4. Kato T,
    5. Tsuboi M,
    6. Lee S-H,
    7. Gao S, et al.
    Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023; 389: 491–503.
    OpenUrlCrossRefPubMed
  9. 9.
    2. Lu S,
    3. Zhang W,
    4. Wu L,
    5. Wang W,
    6. Zhang P,
    7. Fang W, et al.
    Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024; 331: 201–11.
    OpenUrlCrossRefPubMed
  10. 10.
    2. Cascone T,
    3. Awad M,
    4. Spicer J,
    5. He J,
    6. Lu S,
    7. Sepesi B, et al.
    LBA1 CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Ann Oncol. 2023; 34: S1295.
    OpenUrl
  11. 11.↵
    2. Forde P,
    3. Spicer J,
    4. Girard N,
    5. Provencio M,
    6. Lu S,
    7. Wang C, et al.
    84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816. J Thorac Oncol. 2023; 18: S89–90.
    OpenUrl
  12. 12.↵
    2. Provencio M,
    3. Nadal E,
    4. Insa A,
    5. García-Campelo MR,
    6. Casal-Rubio J,
    7. Dómine M, et al.
    Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21: 1413–22.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Zheng S,
    3. Cui X,
    4. Ye Z.
    Integrating artificial intelligence into radiological cancer imaging: from diagnosis and treatment response to prognosis. Cancer Biol Med. 2025; 22: 6–13.
    OpenUrlFREE Full Text
  14. 14.↵
    2. Yang M,
    3. Li X,
    4. Cai C,
    5. Liu C,
    6. Ma M,
    7. Qu W, et al.
    [18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study. Eur Radiol. 2024; 34: 4352–63.
    OpenUrlPubMed
  15. 15.↵
    2. Yang N,
    3. Yue HL,
    4. Zhang BH,
    5. Chen J,
    6. Chu Q,
    7. Wang JX, et al.
    Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features. Thorac Cancer. 2023; 14: 2869–76.
    OpenUrlPubMed
  16. 16.↵
    2. Travis WD,
    3. Dacic S,
    4. Wistuba I,
    5. Sholl L,
    6. Adusumilli P,
    7. Bubendorf L, et al.
    IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020; 15: 709–40.
    OpenUrlPubMed
  17. 17.↵
    2. Yang C,
    3. Huang M,
    4. Li S,
    5. Chen J,
    6. Yang Y,
    7. Qin N, et al.
    Radiomics model of magnetic resonance imaging for predicting pathological grading and lymph node metastases of extrahepatic cholangiocarcinoma. Cancer Lett. 2020; 470: 1–7.
    OpenUrlPubMed
  18. 18.↵
    2. Lundberg SM,
    3. Lee S-I.
    A unified approach to interpreting model predictions. In: Proceedings of the 31st International Conference on Neural Information Processing Systems (NIPS’17). Red Hook, NY, USA: Curran Associates Inc.; 2017: 4768–77.
  19. 19.↵
    2. Plackett RL.
    Karl pearson and the chi-squared test. Int Stat Rev. 1983; 51: 59–72.
    OpenUrl
  20. 20.
    2. Kim TK.
    T test as a parametric statistic. Korean J Anesthesiol. 2015; 68: 540–6.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Ostertagova E,
    3. Ostertag O,
    4. Kováč J.
    Methodology and application of the Kruskal–Wallis test. Appl Mech Mater. 2014; 611: 115–20.
    OpenUrl
  22. 22.↵
    2. DeLong ER,
    3. DeLong DM,
    4. Clarke-Pearson DL.
    Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 837–45.
  23. 23.↵
    2. Bao X,
    3. Peng Q,
    4. Bian D,
    5. Ni J,
    6. Zhou S,
    7. Zhang P, et al.
    Short-term intra-and peri-tumoral spatiotemporal CT radiomics for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Eur Radiol. 2025; 35: 6052–64.
    OpenUrlPubMed
  24. 24.↵
    2. Ye G,
    3. Wu G,
    4. Qi Y,
    5. Li K,
    6. Wang M,
    7. Zhang C, et al.
    Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study. J Immunother Cancer. 2024; 12: e009348.
  25. 25.↵
    2. Eze C,
    3. Schmidt-Hegemann N-S,
    4. Sawicki LM,
    5. Kirchner J,
    6. Roengvoraphoj O,
    7. Käsmann L, et al.
    PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. Eur J Nucl Med Mol Imaging. 2021; 48: 3975–89.
    OpenUrlPubMed
  26. 26.↵
    2. Gao P,
    3. Xiao Q,
    4. Tan H,
    5. Song J,
    6. Fu Y,
    7. Xu J, et al.
    Interpretable multi-modal artificial intelligence model for predicting gastric cancer response to neoadjuvant chemotherapy. Cell Rep Med. 2024; 5: 101848.
  27. 27.↵
    2. Jiang C,
    3. Zhang X,
    4. Qu T,
    5. Yang X,
    6. Xiu Y,
    7. Yu X, et al.
    The prediction of pCR and chemosensitivity for breast cancer patients using DLG3, RADL and Pathomics signatures based on machine learning and deep learning. Transl Oncol. 2024; 46: 101985.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords